The following BRCA1 variants: p.Met18Thr (associated a PFS of 240 days), p.Ser915Phe (PFS: 368 days), and p.Gly928Val (PFS: 136 days), as well as the p.Asp219Gly PALB2 variant (PFS: 224 days), and the p.Ala195Val RAD51C variant (PFS: 210 days), seemed to be linked to tumor sensitivity to olaparib and were classified as deleterious by our algorithm. This evidence concerns the gene BRCA1 and neoplasm.